Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.
Metrics to compare | 373110 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship373110PeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −5.2x | −0.5x | |
PEG Ratio | −0.31 | −0.08 | 0.00 | |
Price/Book | 15.8x | 3.7x | 2.6x | |
Price / LTM Sales | 18.9x | 7.0x | 3.3x | |
Upside (Analyst Target) | - | 244.8% | 46.2% | |
Fair Value Upside | Unlock | 9.2% | 6.6% | Unlock |